351 related articles for article (PubMed ID: 18628403)
21. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.
Avlani VA; Langmead CJ; Guida E; Wood MD; Tehan BG; Herdon HJ; Watson JM; Sexton PM; Christopoulos A
Mol Pharmacol; 2010 Jul; 78(1):94-104. PubMed ID: 20413650
[TBL] [Abstract][Full Text] [Related]
22. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
23. Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.
Berizzi AE; Gentry PR; Rueda P; Den Hoedt S; Sexton PM; Langmead CJ; Christopoulos A
Mol Pharmacol; 2016 Oct; 90(4):427-36. PubMed ID: 27461343
[TBL] [Abstract][Full Text] [Related]
24. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
[TBL] [Abstract][Full Text] [Related]
25. LY2033298, a positive allosteric modulator at muscarinic M₄ receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms.
Gannon RL; Millan MJ
Psychopharmacology (Berl); 2012 Nov; 224(2):231-40. PubMed ID: 22610522
[TBL] [Abstract][Full Text] [Related]
26. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.
Lazareno S; Birdsall B; Fukazawa T; Gharagozloo P; Hashimoto T; Kuwano H; Popham A; Sugimoto M; Birdsall NJ
Life Sci; 1999; 64(6-7):519-26. PubMed ID: 10069518
[TBL] [Abstract][Full Text] [Related]
27. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
[TBL] [Abstract][Full Text] [Related]
28. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.
Thal DM; Sun B; Feng D; Nawaratne V; Leach K; Felder CC; Bures MG; Evans DA; Weis WI; Bachhawat P; Kobilka TS; Sexton PM; Kobilka BK; Christopoulos A
Nature; 2016 Mar; 531(7594):335-40. PubMed ID: 26958838
[TBL] [Abstract][Full Text] [Related]
29. Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.
Jakubík J; Randáková A; El-Fakahany EE; Dolezal V
BMC Pharmacol; 2009 Dec; 9():15. PubMed ID: 20038295
[TBL] [Abstract][Full Text] [Related]
30. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
31. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; El-Fakahany EE; Tucek S
Mol Pharmacol; 1997 Jul; 52(1):172-9. PubMed ID: 9224827
[TBL] [Abstract][Full Text] [Related]
32. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies.
Birdsall NJ; Farries T; Gharagozloo P; Kobayashi S; Lazareno S; Sugimoto M
Mol Pharmacol; 1999 Apr; 55(4):778-86. PubMed ID: 10101037
[TBL] [Abstract][Full Text] [Related]
33. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors.
Michal P; Lysíková M; El-Fakahany EE; Tucek S
Eur J Pharmacol; 1999 Jul; 376(1-2):119-25. PubMed ID: 10440097
[TBL] [Abstract][Full Text] [Related]
34. Structure-based discovery of selective positive allosteric modulators of antagonists for the M
Korczynska M; Clark MJ; Valant C; Xu J; Moo EV; Albold S; Weiss DR; Torosyan H; Huang W; Kruse AC; Lyda BR; May LT; Baltos JA; Sexton PM; Kobilka BK; Christopoulos A; Shoichet BK; Sunahara RK
Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2419-E2428. PubMed ID: 29453275
[TBL] [Abstract][Full Text] [Related]
35. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.
Gregory KJ; Hall NE; Tobin AB; Sexton PM; Christopoulos A
J Biol Chem; 2010 Mar; 285(10):7459-74. PubMed ID: 20051519
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.
Abdul-Ridha A; Lane JR; Mistry SN; López L; Sexton PM; Scammells PJ; Christopoulos A; Canals M
J Biol Chem; 2014 Nov; 289(48):33701-11. PubMed ID: 25326383
[TBL] [Abstract][Full Text] [Related]
37. The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
Watt ML; Rorick-Kehn L; Shaw DB; Knitowski KM; Quets AT; Chesterfield AK; McKinzie DL; Felder CC
Neuropsychopharmacology; 2013 Dec; 38(13):2717-26. PubMed ID: 23907402
[TBL] [Abstract][Full Text] [Related]
38. Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.
Abdul-Ridha A; López L; Keov P; Thal DM; Mistry SN; Sexton PM; Lane JR; Canals M; Christopoulos A
J Biol Chem; 2014 Feb; 289(9):6067-79. PubMed ID: 24443568
[TBL] [Abstract][Full Text] [Related]
39. Discovery and Development of Muscarinic Acetylcholine M
Takai K; Enomoto T
Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284.
Smith DL; Davoren JE; Edgerton JR; Lazzaro JT; Lee CW; Neal S; Zhang L; Grimwood S
Mol Pharmacol; 2016 Sep; 90(3):177-87. PubMed ID: 27382013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
